All News

Deaths due to poor-quality health care represent a substantial challenge for universal coverage in low- and middle-income countries.

Top news of the day from across the health care landscape

Sequential administration of HER2+ therapy and chemotherapy did not affect survival outcomes in patients with breast cancer.

Study establishes real-world efficacy, tolerability, and safety profile of sofosbuvir-based regimens in patients with chronic hepatitis C who have compensated liver cirrhosis.

The Patient Right to Know Drug Prices Act would prohibit insurers and prescription benefit managers from using gag clauses by health insurers and pharmacy benefit managers.

Almirall has received European Commission approval for its plaque psoriasis treatment tildrakizumab (Ilumetri).

The National Comprehensive Cancer Network updated its Clinical Practice Guidelines for kidney cancer to include new recommendations for cabozantinib tablets.

Tildrakizumab (Ilumetri) received approval by the European Commission for the treatment of moderate-to-severe chronic plaque psoriasis.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

When used in combination with an anti-PD-L1 therapy, a novel vaccine plus Diprovocim increased survival in mice with melanoma.

Study shows that it’s cost-effective to use the livers of HCV-positive patients even with the cost of direct-acting antiviral drugs to cure the virus.

As medication experts, pharmacists are integral to team-based care, providing the requisite knowledge for medication therapy management, as well as initiating, modifying and monitoring drug therapy to benefit patient care.

Researchers have identified a potential point of intervention that could prevent the progression of liver damage to cancer.

The vaginal inserts can reduce symptoms such as hot flashes and mood swings.

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

Top news of the day from across the health care landscape.

Study identifies receptor as potential target for reversing liver damage and preventing progression to cancer.

Top news of the day from across the health care landscape.

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

Growth in midlife mortality includes conditions such as heart disease, liver cancer, pulmonary disease, obesity, and neurologic disorders.

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

A second unexpected impurity was shown in 3 lots of Torrent Pharmaceuticals’ recalled drug products during an ongoing FDA investigation.

As growing levels of antibiotic resistance continues to concern health care professionals, the results of a recent study suggest that giving daily probiotic supplements to children can reduce their likelihood of requiring antibiotics.

Pamrevlumab is advancing towards phase 3 clinical development for idiopathic pulmonary fibrosis early next year.

Some researchers propose that vasomotor symptoms may signal physiologic processes that might be associated with other related systemic health diagnoses.

Presenters at the International Pharmaceutical Federation (FIP) World Congress in Glasgow, Scotland identified the current landscape of Hepatitis C, how pharmacists can position themselves to aid in point of care testing, and ways to better educate patients and providers.

Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with hairy cell leukemia.

The FDA has accepted for review Regeneron Pharmaceuticals’ supplemental Biologics License Application (sBLA) of aflibercept (EYLEA Injection) to treat diabetic retinopathy.